UPCC 16517: A Phase 1 First-in-Human Open-Label Dose Escalation Study of JNJ-61186372 a Human Bispecific EGFR and cMet Antibody in Subjects with Advanced Non-Small Cell Lung Cancer
Brief description of study
The purpose of this study is to see if JNJ-61186372 is safe and useful for treating patients with advanced, metastatic, non-small cell lung cancer (NSCLC).
Eligibility of study
You may be eligible for this study if you meet the following criteria:
-
Conditions:
['Non-Small-Cell Lung Cancer']
-
Age: - 99 Years
-
Gender: All
Updated on
30 Jan 2020.
Study ID: 828637
